CD86 and neoplasm: This allows maturation of DCs that have taken up tumor antigens, which is required to trigger functional T- and B cell responses against potential tumor-specific neoantigens in tumor-draining lymph nodes via costimulatory signals like CD40, CD80 or CD86 (2).